CEBPA and acute myeloid leukemia: Although FLT3-ITD, Nucleophosmin-1 gene (NPM1) and CCAT/enhancer binding protein a gene (CEBPA) mutations have become established as prognostic markers in cytogenetically normal AML (CN-AML), there is a large group of patients without these mutations (4).